跳至主要内容
临床试验/NCT06521528
NCT06521528进行中(未招募)不适用

A Pilot Clinical Study to Evaluate the Feasibility of Using the Single Patient Classifier as a Prognostic Test in Stage II-III Gastric Cancer Patients.

Novomics. Co., Ltd.1 个研究点 分布在 1 个国家目标入组 237 人开始时间: 2019年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
237
试验地点
1
主要终点
Timely delivered proportion

研究概览

简要总结

Precision medicine approaches emphasize the importance of reliable prognostic tools for guiding individualized therapy decisions. In this study, we evaluated the clinical feasibility of the Single Patient Classifier (SPC) test, a new clinical-grade prognostic assay, in stage II-III gastric cancer patients.

详细描述

A prospective multicenter study was conducted, involving 237 patients who underwent gastrectomy between September 2019 and August 2020 across nine hospitals. The SPC test was employed to stratify patients into risk groups, and its feasibility and performance were evaluated. The primary endpoint was the proportion of the cases in which the test results were timely delivered before selecting postoperative treatment. Furthermore, 3-year disease-free survivals of risk groups were analyzed.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • being ≥19 years of age
  • having a histologically confirmed diagnosis of stage II or III AGC according to the American Joint Committee on Cancer (AJCC) staging system (sixth edition)
  • underwent radical gastrectomy without prior neo-adjuvant chemoradiotherapy and did not receive adjuvant chemotherapy
  • having no visually or microscopically detectable residual tumors.

排除标准

  • Those with insufficient quantity or quality of ribonucleic acid (RNA) for analysis were excluded from the study.

结局指标

主要结局

Timely delivered proportion

时间窗: 14 days

the proportion of the cases in which the test results were timely delivered before selecting postoperative treatment

次要结局

  • 3-year disease free survival of the enrolled patients.(3-years after the enrollment completion)
  • 5-year overall survival of the enrolled patients.(5-years after the enrollment completion)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验